<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mpath ids='MPATH_589'>Dysplasia</z:mpath> in <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> has been recognized to be morphologically heterogenous, featuring adenomatous, foveolar, and hybrid phenotypes </plain></SENT>
<SENT sid="1" pm="."><plain>Recent studies have suggested a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor role for <z:chebi fb="8" ids="3479">CDX</z:chebi>-2 in the <z:mpath ids='MPATH_160'>metaplasia</z:mpath>-<z:mpath ids='MPATH_589'>dysplasia</z:mpath>-<z:mp ids='MP_0002038'>carcinoma</z:mp> sequence </plain></SENT>
<SENT sid="2" pm="."><plain>The phenotypic stability and role of <z:chebi fb="8" ids="3479">CDX</z:chebi>-2 in the <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> of different types of <z:mpath ids='MPATH_589'>dysplasias</z:mpath> have not been evaluated </plain></SENT>
<SENT sid="3" pm="."><plain>Thirty-eight endoscopic mucosal resections with <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and/or intramucosal <z:mp ids='MP_0002038'>carcinoma</z:mp> (IMC) arising in <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> were evaluated for the expression of MUC5AC, MUC6, MUC2, CD10, and <z:chebi fb="8" ids="3479">CDX</z:chebi>-2 </plain></SENT>
<SENT sid="4" pm="."><plain>The background mucosa was also evaluated </plain></SENT>
<SENT sid="5" pm="."><plain>The results were correlated with morphologic classification and clinicopathologic parameters </plain></SENT>
<SENT sid="6" pm="."><plain>Of 38 endoscopic mucosal resections, 23 had IMC and <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, 8 had IMC only, and 7 had <z:mpath ids='MPATH_589'>dysplasia</z:mpath> only </plain></SENT>
<SENT sid="7" pm="."><plain>Among dysplastic lesions, 73% were foveolar, 17% were adenomatous, and 10% were hybrid </plain></SENT>
<SENT sid="8" pm="."><plain>Twenty of 23 cases with <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and adjacent IMC showed an identical immunophenotype of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and IMC comprising 16 gastric, 3 intestinal, and 1 mixed immunophenotype </plain></SENT>
<SENT sid="9" pm="."><plain>Three cases showed discordance of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and IMC immunophenotype </plain></SENT>
<SENT sid="10" pm="."><plain>These findings suggest that most Barrett-related IMC cases are either gastric or intestinal, with phenotypic stability during progression supporting separate gastric and intestinal pathways of <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="8" ids="3479">CDX</z:chebi>-2 showed gradual downregulation of expression during progression in adenomatous <z:mpath ids='MPATH_589'>dysplasia</z:mpath> but not in foveolar or hybrid <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, supporting a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor role, at least in the intestinal pathway </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="8" ids="3479">CDX</z:chebi>-2 was also found to be expressed to a greater degree in <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> compared with nonintestinalized columnar <z:mpath ids='MPATH_160'>metaplasia</z:mpath> </plain></SENT>
<SENT sid="13" pm="."><plain>Consistent with <z:chebi fb="8" ids="3479">CDX</z:chebi>-2 as a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor, this suggests that nonintestinalized columnar <z:mpath ids='MPATH_160'>metaplasia</z:mpath> may be an unstable intermediate state at risk for <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> </plain></SENT>
</text></document>